VJOncology is committed to improving our service to you

ASCO 2017 | Is the current dose of pembrolizumab approved for treating lung cancer too high?

VJOncology is committed to improving our service to you

Daniel Goldstein

Daniel Goldstein, MD, from Davidoff Cancer Center, Petah Tikva, Israel, talks to us about the possibility of lowering the current FDA-approved dose of pembrolizumab for the treatment of PD-L1-positive lung cancer and notes that studies have shown equivalent efficacies of the drug in two different doses. He states that lowering the prescription dose from 200mg, the FDA-approved dose, to 150mg, may save $0.8 billion annually, whilst maintaining the same level of efficacy in patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter